Page 89 - CIBEREHD2016-ENG

Most relevant scientific articles
• De Avila A.I., Gallego I., Soria M.E., Gregori J., Quer J., Ignacio Esteban J. et al. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS ONE. 2016;11(10).
• Ariza-Mateos A., Diaz-Toledano R., Block T.M., Prieto-Vega S., Birk A., Gomez J. Geneticin stabilizes the open conformation of the 5′ region of hepatitis C virus RNA and inhibits viral replication. Antimicrobial Agents and Chemotherapy. 2016;60(2):925-935.
• Gregori J., Perales C., Rodriguez-Frias F., Esteban J.I., Quer J., Domingo E. Viral quasispecies complexity measures. Virology. 2016; 493:227-237.
• Gallego I, Sheldon J, Moreno E, Gregori J, Quer J, Esteban JI et al. Barrier-Independent, Fitness- Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.Antimicrobial agents and chemotherapy. 2016;60(6):3786-93.
• Quer J., Rodriguez-Frias F., Gregori J., Tabernero D., Soria M.E., Garcia-Cehic D. et al. Deep sequencing in the management of hepatitis virus infections. Virus Research. 2016.
Hightlights
The joint CSIC molecular virology group was formed in 2007 to bring together scientists investigating the structural and evolutionary aspects of the hepatitis C virus in terms of viral targets, their therapeutic agents and the resistances HCV acquieres to therapeutic agents. Most reported activities are collaborations with a number of CIBEREHD members from other research groups. Concerned with the quasispecies nature of the HCV genome and its high rate of evolution, our studies focus on two main premises: firstly, that HCV fitness may play a part in reducing viral sensitivity to the drug sofosbuvir; and secondly, that favipiravit, a new drug used to treat influenza, offers a novel option for HCV treatment. This is because its mechanism of action acts at least partially through a lethal mutagenesis during RNA replication. With regard to RNA structures present in the 5’ region of the HCV genome, we found that Geneticin®, a well-known antibiotic agent that binds to the bacterial ribosomal RNA, can also impede the structural switch of HCV RNA in the 5’ region and inhibit viral replication.
EHD
research Groups 89